Compounds having MIF antagonist activity

US6492428B1 · kind B1 · utility

Assignee

• The Picower Institute for Medical Research · US

Inventors

• Yousef Al-Abed · Dix Hills, US
• Richard J. Bucala · New York, US
• Robert A. Mitchell · Fort Mill, US
• Peter D. Senter · Seattle, US

Key dates

• Filing date: Jul 26, 2000
• Grant date: Dec 10, 2002
• Expiry date: Jul 26, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are disclosed methods of use and pharmaceutical compositions for two related genera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MIF (macrophage migration inhibitory factor) antagonist activity and find utility as such. For example, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, EAE, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).